CTOs on the Move

Quadrant Biosciences

www.quadrantbiosciences.com

 
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Charles Marra
 Vice President of Technology Profile
Nick Gianadda
 Chief Technology Officer Profile

Similar Companies

HealthSource Solutions

HealthSource Solutions is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Halo Labs

Halo Labs is all about particle analysis. We live to find particles, analyze them, count them, and help our customers characterize them to better their biopharmaceutical products.

Cambria Biosciences

Cambria Biosciences is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eidos Therapeutics

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.

Miraculins

Miraculins is a pre-revenue biotechnology company that acquires, develops and commercializes new, non-invasive diagnostic and risk assessment tests to aid physicians in the earlier diagnosis of disease. The Company specializes in the development and manufacturing of medical devices and has been successfully accessing capital on the public markets as required to finance its operations to date. It is currently preparing for transition to a commercialization phase. Miraculins began as a research and development company in 2002, with a focus on biomarker discovery. In June of 2008, the company shifted its focus to diagnostic asset development where it began to in-license and acquire diagnostic and risk assessment technologies that had completed early stage research and addressed significant unmet medical needs in the U.S., Canada, and global markets.